BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
Portfolio Pulse from
Biogen Inc. (BIIB) has initiated a Phase III study for its drug felzartamab, targeting adult kidney transplant recipients with late antibody-mediated rejection (AMR). The study, named TRANSCEND, aims to enroll around 120 patients.
March 12, 2025 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen has started a Phase III study for felzartamab in kidney transplant patients with late AMR, potentially advancing its product pipeline.
The initiation of a Phase III study is a significant step in drug development, indicating progress in Biogen's product pipeline. Successful results could lead to regulatory approval and market expansion, positively impacting BIIB's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100